Drug Profile
HL 1513
Alternative Names: HL1513Latest Information Update: 24 May 2016
Price :
$50
*
At a glance
- Originator Handok Inc
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 01 Oct 2013 Phase-I clinical trials in Type-1 diabetes mellitus in South Korea (unspecified route)